Intellectual resource management in pharmaceutical developments for the treatment of diabetes mellitus type II

Abstract

It has established active patenting of glucagon-like peptide-1 receptor agonists (GLP-1: liraglutide US6268343, lixisenatide US10028910), able to regulate glycemia by influencing the secretion of insulin and glucagon depending on its level. Another new treatment strategy aimed at incretin gut hormones – inhibitors of dipeptidyl peptidase (DPP-4: sitagliptin US7326708, vildagliptin, saxagliptin US7951400, alogliptin US7807689, linagliptin US7407955). It has established the effectiveness of sodium-dependent glucose transporter (SGLT2: dapagliflozin US7456254, kanagliflozin US7943582, empagliflozin US9949997 ). These drugs are under patent protection and are represented on the Ukrainian market by foreign pharmaceutical companies. Currently, most clinical guidelines recommend the use of the mentioned preparations of new classes as drugs of the third choice.The promising areas in the treatment of diabetes include the combined use of metformin and GLP-1, DPP-4, SGLT2 (UA104136, UA100008, UA102429).